Roche Diagnostics aims to be No 1 in immunochemistry
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is aiming to overtake Abbott Laboratories within five years to become the leading company in the field of immunochemistry, writes Eleanor Malone. The Swiss company says it currently has a share of around 15% of the SwFr8.6bn ($7.2bn) market, against Abbott's 22%.